Evidence map›Paper›PMID 21934653›Full record

ArticleMolecular therapy : the journal of the American Society of Gene Therapy2011

Co-operative membrane disruption between cell-penetrating peptide and cargo: implications for the therapeutic use of the Bcl-2 converter peptide D-NuBCP-9-r8.

Catherine L Watkins, Edward J Sayers, Chris Allender, David Barrow, Christopher Fegan, Paul Brennan, Arwyn T Jones

Abstract read
In one paragraph

Article in Molecular therapy : the journal of the American Society of Gene Therapy, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Catherine L WatkinsWelsh School of Pharmacy, Cardiff University, Cardiff, UK.
Edward J Sayers
Chris Allender
David Barrow
Christopher Fegan
Paul Brennan
Arwyn T Jones

Funding

Biotechnology and Biological Sciences Research Council BB/D013038/1Biotechnology and Biological Sciences Research Council D013038
6 · The paper itself

Abstract

Delivering apoptosis inducing peptides to cells is an emerging area in cancer and molecular therapeutics. Here, we have identified an alternative mechanism of action for the proapoptotic chimeric peptide D-NuBCP-9-r8. Integral to D-NuBCP-9-r8 is the Nur-77-derived D-isoform sequence fsrslhsll that targets Bcl-2, and the cell-penetrating peptide (CPP) octaarginine (r8) that is required for intracellular delivery. We find that the N-terminal phenylalanine of fsrslhsll acts in synergy with the cell-penetrating moiety to enhance peptide uptake at low nontoxic levels and cause rapid membrane blebbing and cell necrosis at higher (IC(50)) concentrations. These effects were not observed when a single phenylalanine-alanine mutation was introduced at the N-terminus of D-NuBCP-9-r8. Using primary samples from chronic lymphocytic leukemia (CLL) patients and cancer cell lines, we show that NuBCP-9-r8 induced toxicity, via membrane disruption, is independent of Bcl-2 expression. Overall, this study demonstrates a new mechanism of action for this peptide and cautions its use as a highly specific entity for targeting Bcl-2. For delivery of therapeutic peptides the work emphasizes that key amino acids in cargo, located several residues away from the cell-penetrating sequence, can significantly influence their cellular uptake and mode of action.

Indexed as

Cell Membrane PermeabilityApoptosisBiological TransportCell Line, TumorCell MembraneCell-Penetrating PeptidesHumansLeukemia, Lymphocytic, Chronic, B-CellNuclear Receptor Subfamily 4, Group A, Member 1OligopeptidesProto-Oncogene Proteins c-bcl-2Tissue DistributionCell-Penetrating PeptidesNR4A1 protein, humanNuclear Receptor Subfamily 4, Group A, Member 1Oligopeptidesphenylalanyl-seryl-arginyl-seryl-leucyl-histidyl-seryl-leucyl-leucineProto-Oncogene Proteins c-bcl-2

Identifiers

PMID21934653
PMCPMC3232455

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.